FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2155059637> ?p ?o ?g. }

• W2155059637 endingPage "1084" @default.
• W2155059637 startingPage "1075" @default.
• W2155059637 abstract "Purpose To assess cost effectiveness of radioembolization versus conventional transarterial chemoembolization. Materials and Methods The cost of radioembolization versus conventional transarterial chemoembolization was determined based on Medicare reimbursements. Three patient subgroups were defined based on the Barcelona Clinic Liver Cancer (BCLC) classification system (A, B, or C). Efficacy and safety outcomes after each procedure were obtained from the literature. A Monte Carlo case-based simulation was designed for 60 months in 250 patients in each subgroup. Survival was calculated based on average survival from the literature and the Monte Carlo model. The primary outcome was the cost effectiveness of radioembolization over transarterial chemoembolization by considering calculated survival. Results The costs approached $17,000 for transarterial chemoembolization versus $31,000 or $48,000 for unilobar or bilobar radioembolization, respectively. Based on the simulation, median estimated survival was greater with transarterial chemoembolization than radioembolization in BCLC-A and BCLC-B subgroups (40 months vs 30 months and 23 months vs 16 months, respectively, P = .001). However, in the BCLC-C subgroup, survival was greater with radioembolization than transarterial chemoembolization (13 months vs 17 months, P = .001). The incremental cost-effectiveness ratio of radioembolization over transarterial chemoembolization in the BCLC-C subgroup was $360 per month. The results were dependent on bilobar versus unilobar radioembolization and the total number of radioembolization procedures. Conclusions The model suggests radioembolization costs may be justified for patients with BCLC-C disease, whereas radioembolization may not be cost effective in patients with BCLC-A disease; however, many patients with BCLC-C disease have extensive disease precluding locoregional therapies. Secondary considerations may determine treatment choice in more borderline patients (BCLC-B disease) because there is no persistent survival benefit with radioembolization." @default.
• W2155059637 created "2016-06-24" @default.
• W2155059637 creator A5002263778 @default.
• W2155059637 creator A5021826780 @default.
• W2155059637 creator A5040047613 @default.
• W2155059637 creator A5042155309 @default.
• W2155059637 creator A5044107299 @default.
• W2155059637 date "2014-07-01" @default.
• W2155059637 modified "2023-10-12" @default.
• W2155059637 title "Cost Effectiveness of Radioembolization Compared with Conventional Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma" @default.
• W2155059637 cites W1964204941 @default.
• W2155059637 cites W1964696633 @default.
• W2155059637 cites W1966969960 @default.
• W2155059637 cites W1968626722 @default.
• W2155059637 cites W1975154077 @default.
• W2155059637 cites W1981536905 @default.
• W2155059637 cites W1982153769 @default.
• W2155059637 cites W1986393349 @default.
• W2155059637 cites W1990295946 @default.
• W2155059637 cites W1991066595 @default.
• W2155059637 cites W1992463603 @default.
• W2155059637 cites W1998417832 @default.
• W2155059637 cites W2004261972 @default.
• W2155059637 cites W2004564435 @default.
• W2155059637 cites W2010042995 @default.
• W2155059637 cites W2011411108 @default.
• W2155059637 cites W2016199951 @default.
• W2155059637 cites W2025858981 @default.
• W2155059637 cites W2027006358 @default.
• W2155059637 cites W2027132351 @default.
• W2155059637 cites W2029079150 @default.
• W2155059637 cites W2031318932 @default.
• W2155059637 cites W2031896753 @default.
• W2155059637 cites W2034618725 @default.
• W2155059637 cites W2036806360 @default.
• W2155059637 cites W2039963442 @default.
• W2155059637 cites W2040480360 @default.
• W2155059637 cites W2046516248 @default.
• W2155059637 cites W2048601821 @default.
• W2155059637 cites W2050748799 @default.
• W2155059637 cites W2051842222 @default.
• W2155059637 cites W2059743929 @default.
• W2155059637 cites W2066593706 @default.
• W2155059637 cites W2066998654 @default.
• W2155059637 cites W2070339511 @default.
• W2155059637 cites W2071618269 @default.
• W2155059637 cites W2075242521 @default.
• W2155059637 cites W2077014377 @default.
• W2155059637 cites W2084244015 @default.
• W2155059637 cites W2086776840 @default.
• W2155059637 cites W2088032995 @default.
• W2155059637 cites W2091712865 @default.
• W2155059637 cites W2092377509 @default.
• W2155059637 cites W2098618036 @default.
• W2155059637 cites W2103426950 @default.
• W2155059637 cites W2104740603 @default.
• W2155059637 cites W2107333349 @default.
• W2155059637 cites W2109712769 @default.
• W2155059637 cites W2110802064 @default.
• W2155059637 cites W2120746506 @default.
• W2155059637 cites W2129802081 @default.
• W2155059637 cites W2131212067 @default.
• W2155059637 cites W2134338345 @default.
• W2155059637 cites W2136462552 @default.
• W2155059637 cites W2137310547 @default.
• W2155059637 cites W2138424758 @default.
• W2155059637 cites W2144288516 @default.
• W2155059637 cites W2148574277 @default.
• W2155059637 cites W2158931061 @default.
• W2155059637 cites W2160554202 @default.
• W2155059637 cites W2163557371 @default.
• W2155059637 cites W2164654252 @default.
• W2155059637 cites W2165336841 @default.
• W2155059637 cites W2316538886 @default.
• W2155059637 cites W2346525155 @default.
• W2155059637 cites W2915588212 @default.
• W2155059637 doi "https://doi.org/10.1016/j.jvir.2014.04.014" @default.
• W2155059637 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24861664" @default.
• W2155059637 hasPublicationYear "2014" @default.
• W2155059637 type Work @default.
• W2155059637 sameAs 2155059637 @default.
• W2155059637 citedByCount "45" @default.
• W2155059637 countsByYear W21550596372015 @default.
• W2155059637 countsByYear W21550596372016 @default.
• W2155059637 countsByYear W21550596372017 @default.
• W2155059637 countsByYear W21550596372018 @default.
• W2155059637 countsByYear W21550596372019 @default.
• W2155059637 countsByYear W21550596372020 @default.
• W2155059637 countsByYear W21550596372021 @default.
• W2155059637 countsByYear W21550596372022 @default.
• W2155059637 countsByYear W21550596372023 @default.
• W2155059637 crossrefType "journal-article" @default.
• W2155059637 hasAuthorship W2155059637A5002263778 @default.
• W2155059637 hasAuthorship W2155059637A5021826780 @default.
• W2155059637 hasAuthorship W2155059637A5040047613 @default.
• W2155059637 hasAuthorship W2155059637A5042155309 @default.
• W2155059637 hasAuthorship W2155059637A5044107299 @default.
• W2155059637 hasConcept C126322002 @default.

• next